Mainz Biomed BV (MYNZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mainz Biomed BV (MYNZ) has a cash flow conversion efficiency ratio of -6.957x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.46 Million) by net assets ($641.60K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MYNZ cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Mainz Biomed BV - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Mainz Biomed BV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mainz Biomed BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mainz Biomed BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Media Tbk
JK:KBLV
|
-0.001x |
|
Viking Mines Ltd
AU:VKA
|
-0.290x |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
-0.039x |
|
Cahayaputra Asa Keramik Tbk PT
JK:CAKK
|
0.138x |
|
Thai Coating Industrial Public Company Limited
BK:TCOAT
|
-0.006x |
|
Pryme BV
OL:PRYME
|
-1.603x |
|
ECOUP OYJ EO 1
F:62H
|
N/A |
|
SWS Capital Bhd
KLSE:7186
|
0.005x |
Annual Cash Flow Conversion Efficiency for Mainz Biomed BV (2019–2025)
The table below shows the annual cash flow conversion efficiency of Mainz Biomed BV from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see MYNZ company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $641.60K | $-10.98 Million | -17.113x | -505.46% |
| 2024-12-31 | $6.05 Million | $-17.09 Million | -2.826x | +58.14% |
| 2023-12-31 | $3.25 Million | $-21.94 Million | -6.752x | -544.41% |
| 2022-12-31 | $14.10 Million | $-14.77 Million | -1.048x | -106.97% |
| 2021-12-31 | $6.36 Million | $-3.22 Million | -0.506x | -396.10% |
| 2020-12-31 | $-2.74 Million | $-468.74K | 0.171x | -19.94% |
| 2019-12-31 | $-1.95 Million | $-416.50K | 0.214x | -- |
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more